Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases.

Circ Res

From the Department of Biology, San Diego State Heart Institute, San Diego State University, CA (S.D., M.H.K., B.J., J.E., M.V., H.T., B.C., L.O., K.S., A.D.L.T., M.A.S.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla (D.A.K., A.B.G.); and Department of Medicine, Medical University of South Carolina Hollings Cancer Center, Charleston (A.S.K.), and Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.P.K.).

Published: July 2014

AI Article Synopsis

  • The study investigates how the loss of Pim kinases contributes to cardiac aging by impairing mitochondrial function and energy production.
  • It finds that genetic deletion of Pim kinases in mice leads to early signs of heart failure, metabolic dysfunction, and cellular changes associated with aging.
  • The research concludes that Pim kinases play a crucial role in protecting heart health and maintaining mitochondrial integrity, offering insights that could help counteract cardiac aging.

Article Abstract

Rationale: The senescent cardiac phenotype is accompanied by changes in mitochondrial function and biogenesis causing impairment in energy provision. The relationship between myocardial senescence and Pim kinases deserves attention because Pim-1 kinase is cardioprotective, in part, by preservation of mitochondrial integrity. Study of the pathological effects resulting from genetic deletion of all Pim kinase family members could provide important insight about cardiac mitochondrial biology and the aging phenotype.

Objective: To demonstrate that myocardial senescence is promoted by loss of Pim leading to premature aging and aberrant mitochondrial function.

Methods And Results: Cardiac myocyte senescence was evident at 3 months in Pim triple knockout mice, where all 3 isoforms of Pim kinase family members are genetically deleted. Cellular hypertrophic remodeling and fetal gene program activation were followed by heart failure at 6 months in Pim triple knockout mice. Metabolic dysfunction is an underlying cause of cardiac senescence and instigates a decline in cardiac function. Altered mitochondrial morphology is evident consequential to Pim deletion together with decreased ATP levels and increased phosphorylated AMP-activated protein kinase, exposing an energy deficiency in Pim triple knockout mice. Expression of the genes encoding master regulators of mitochondrial biogenesis, PPARγ (peroxisome proliferator-activated receptor gamma) coactivator-1 α and β, was diminished in Pim triple knockout hearts, as were downstream targets included in mitochondrial energy transduction, including fatty acid oxidation. Reversal of the dysregulated metabolic phenotype was observed by overexpressing c-Myc (Myc proto-oncogene protein), a downstream target of Pim kinases.

Conclusions: Pim kinases prevent premature cardiac aging and maintain a healthy pool of functional mitochondria leading to efficient cellular energetics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254755PMC
http://dx.doi.org/10.1161/CIRCRESAHA.115.304441DOI Listing

Publication Analysis

Top Keywords

pim triple
16
triple knockout
16
pim
12
pim kinases
12
knockout mice
12
metabolic dysfunction
8
premature aging
8
deletion pim
8
myocardial senescence
8
pim kinase
8

Similar Publications

UM171 suppresses breast cancer progression by inducing KLF2.

Breast Cancer Res Treat

September 2024

State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, Guizhou, People's Republic of China.

Article Synopsis
  • The study investigates the anti-cancer effects of UM171, a compound previously linked to hematopoietic stem cell renewal, on various breast cancer cell lines and aims to determine its mechanism of action.
  • Results show that UM171 effectively inhibits breast cancer cell growth, induces apoptosis, causes cell cycle arrest, and reduces cell migration and colony-forming capacity.
  • In an animal model, UM171 significantly suppressed tumor growth in triple-negative breast cancer, and its effectiveness was associated with increased expression of KLF2 and PIM genes, with KLF2 knockdown reducing UM171’s anti-cancer activity.
View Article and Find Full Text PDF
Article Synopsis
  • Two new enzyme replacement therapies for late-onset Pompe disease received approval from the European Medicines Agency between 2022 and 2023, prompting an update to treatment guidelines by the European Pompe Consortium (EPOC).
  • The EPOC, consisting of 25 experts from eight countries, developed a consensus on when to start, switch, or stop ERT based on in-person meetings and discussions.
  • Recommendations emphasize starting ERT in symptomatic patients, criteria for switching treatments based on muscle function stabilization, and the option of stopping ERT if there are severe reactions or lack of improvement, with regular assessments every six months to monitor progress.
View Article and Find Full Text PDF

Background: Understanding why some triple-negative breast cancer (TNBC) patients respond poorly to existing therapies while others respond well remains a challenge. This study aims to understand the potential underlying mechanisms distinguishing early-stage TNBC tumors that respond to clinical intervention from non-responders, as well as to identify clinically viable therapeutic strategies, specifically for TNBC patients who may not benefit from existing therapies.

Methods: We conducted retrospective bioinformatics analysis of historical gene expression datasets to identify a group of genes whose expression levels in early-stage tumors predict poor clinical outcomes in TNBC.

View Article and Find Full Text PDF

PIM3 Kinase: A Promising Novel Target in Solid Cancers.

Cancers (Basel)

January 2024

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Article Synopsis
  • PIM3 is a serine/threonine kinase and part of the PIM family, identified as a proto-oncogene frequently overexpressed in various cancers, particularly from endoderm-derived tissues like liver and breast.
  • It plays a key role in enhancing cancer cell behaviors such as proliferation, survival, and resistance to treatments, making it a significant target for cancer therapies.
  • Despite ongoing clinical trials for pan-PIM inhibitors, there are currently no FDA-approved treatments targeting PIM3, highlighting the need for further research in this area.
View Article and Find Full Text PDF

PIM kinases are over-expressed by a number of solid malignancies including breast cancer, and are thought to regulate proliferation, survival, and resistance to treatment, making them attractive therapeutic targets. Because PIM kinases sit at the nexus of multiple oncodriver pathways, PIM antagonist drugs are being tested alone and in conjunction with other therapies to optimize outcomes. We therefore sought to test the combination of pharmacological PIM antagonism and Th1-associated immunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!